Viatris Inc. (VTRS)
VTRSNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$21.20
+0.1400 (+0.66%) today
At the close, Nov 11, 4:00 PM ET. Pre-market $21.20 +0.66%
- Market cap
- $24.30bn
- P/E
- 8.3
- EPS, last 4 quarters
- $2.56
- Dividend yield
- 2.30%
- Day range
- –
- 52-week range
- $10.15 to $20.86
- Average volume
- –
- Previous close
- $21.06
Analysts
9 coveringBuy5 buy, 3 hold, 1 sell
Targets a year out average $20.67, -2.5% from here
Earnings
next estimate $0.6000Next report
Dec 2025
+9.6%
Mar 2026
+13.5%
Jun 2026
+11.3%
Sep 2026
+10.9%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $3.70bn | $3.52bn | $3.76bn | $3.75bn |
| Gross profit | $1.15bn | $1.16bn | $1.46bn | $1.44bn |
| Operating income | -$192.70m | -$79.70m | $6.30m | $261.50m |
| Net income | -$340.10m | $176.40m | -$118.80m | -$325.30m |
Last four quarters: revenue $14.73bn, margin -4.1%, free cash flow $2.11bn
News
8 latest- Noteworthy Wednesday Option Activity: VTRS, LULU, UNHBNK Invest · 16 hours ago
- VTRS or DHR: Which Is the Better Value Stock Right Now?Zacks · 1 day ago
- Viatris Inc. (VTRS) Hit a 52 Week High, Can the Run Continue?Zacks · 1 day ago
- Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?Zacks · 6 days ago
- Vitaris' Q3 Loss Expands To $325 Mln Despite Consistent Sales; 2026 Guidance Raised RTTNews · 6 days ago
- Viatris Inc. Reports Third-Quarter 2026 Total Revenues of $3.75 Billion and Raises Full-Year GuidanceFintel · 6 days ago
- Viatris (VTRS) Q3 2026 Earnings Call TranscriptThe Motley Fool · 7 days ago
- Here's What Key Metrics Tell Us About Viatris (VTRS) Q3 EarningsZacks · 7 days ago
The company
Viatris Inc . (Nasdaq: VTRS) is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. We meet the needs of patients around the world by acting decisively with ingenuity and resolve. Whether we're developing new medicines, working to maintain a resilient supply of needed therapies, or pursuing bold innovation, we strive to deliver solutions that are effective at scale and built to endure. We're purpose-built to make an impact with a broad portfolio that spans generics, value-added medicines, established brands and innovative medicines that address areas of significant unmet need. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com , and connect with us on LinkedIn , Instagram , YouTube and X .
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- viatris.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.